by Madaline Spencer | Aug 11, 2025
Dirk Arnold, MD, PhD, Director of the Asklepios Tumorzentrum Hamburg, discusses results from the OrigAMI-1 clinical trial in left-sided RAS/BRAF wild-type metastatic colorectal cancer (mCRC). Approximately 50% of patients diagnosed with colorectal cancer...
by Madaline Spencer | Aug 10, 2025
Skand Shekhar, MD, Principal Investigator at the National Institutes of Health (NIH), discusses Erdheim-Chester disease diagnosis and treatment options. ECD is a rare blood cancer characterized by the overproduction of histiocytes, which then accumulate...
by Madaline Spencer | Aug 8, 2025
The U.S. Food and Drug Administration (FDA) has approved Alhemo (concizumab) injection as a once-daily prophylaxis treatment to prevent or reduce frequency of bleeding episodes in patients ages 12 years and older with hemophilia A or B without inhibitors. This is an...
by Madaline Spencer | Aug 7, 2025
Javier Oesterheld, MD, Division Chief of the Cancer and Blood Disorders Program at Levine Children’s Hospital and Founder and Executive Director of the ARISE Cancer Consortium, discusses the organization’s goals and upcoming clinical trials. The ARISE...
by Madaline Spencer | Aug 6, 2025
James Hamrick, MD, Chairman of the Caris Precision Oncology Alliance, discusses age in risk stratification in patients with mutant isocitrate dehydrogenase (mIDH) glioma. mIDH is a rare metabolic gene that causes tumor initiation in many gliomas and...
